香港航天科技(01725.HK)續飆近19%創逾五個月高 中國今年擬發射共三艘飛船
香港航天科技(01725.HK)八連升,今日(16日)高開2.2%後,升幅急擴,最高見17.8元創逾五個月高。現報17.7元,升18.79%,成交4,038.14萬股,涉資6.8億元。另中航科工(02357.HK)現升2.3%,報4元,成交921.1萬股,涉資3,628.69萬元。
中國載人航天工程辦公室公布,去年底中國空間站全面建成後,中國載人空間站工程正式進入應用與發展階段,每年將發射兩艘載人飛船,1至2艘貨運飛船。
按照飛行任務規劃,計劃2023年5月發射天舟六號貨運飛船;5月發射神舟十六號載人飛船;10月發射神舟十七號載人飛船。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.